COMMON STOCK PURCHASE WARRANT ACHIEVE LIFE SCIENCES, INC.Common Stock Purchase Warrant • June 3rd, 2019 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJune 3rd, 2019 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund, Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 30, 2025 (the “ Termination Date ”) but not thereafter, to subscribe for and purchase from Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), up to 1,200,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • June 3rd, 2019 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledJune 3rd, 2019 Company Industry JurisdictionThis Warrant Exercise Agreement (this “Agreement”), dated as of May 30, 2019, is by and between Achieve Life Sciences, Inc., a Delaware corporation (“Company”), and Armistice Capital Master Fund, Ltd. (“Holder”).